COMPANY

Sparian Biosciences, Inc

sparianbiosciences.com ↗ · Mid-Atlantic

Clinical Phase 1

Also known as Sparian Biosciences · 13 sources

Profile checked Oct 10, 2026

Keywords: Pain Acute Acute Pain opioid use disorder SBS-147 SBS-1000

2Trials (company is sponsor)7NIH grants

Funding and NIH signals

NIH award NIH awarded $3.08M (NIH grant 5UG3DA064392-02, continuation, notice Jun 16, 2026). NIH RePORTER 5UG3DA064392-02 (Jun 16, 2026)
Evidence (1 event)
- Jun 16, 2026 · NIH RePORTER 5UG3DA064392-02
  Organization: SPARIAN BIOSCIENCES, INC.; City/State: NEW YORK CITY, NY; Project number: 5UG3DA064392-02; Activity code: UG3; Fiscal year: 2026; Award notice date: 2026-06-16; FY total cost (award amount): 3084524; Administering IC: National Institute on Drug Abuse; Project title: Clinical Development of SBS-147: First-in-class Oral Arylepoxamide Agonist for Pain; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Jun 16, 2026 Grant Government grant — NIH UG3: $3.08M (annual award, as published), announced Jun 16, 2026. Agency: NIH/NIDA. Source: government award database. source ↗
Jan 8, 2026 Trial start 1: Phase 1 Study of SBS-147 in Healthy Adults source ↗
Jul 29, 2025 Grant Government grant — NIH UG3: $3.98M (annual award, as published), announced Jul 29, 2025. Agency: NIH/NIDA. Source: government award database. source ↗
Jun 26, 2025 Grant Government grant — NIH UG3: $3.14M (annual award, as published), announced Jun 26, 2025. Agency: NIH/NIDA. Source: government award database. source ↗
Nov 14, 2024 Grant Government grant: $19.5M (total, as published), announced Nov 14, 2024. Source: company release on GlobeNewswire. source ↗
Jan 30, 2023 Trial start 1: A Phase 1, Randomized, Placebo-Controlled Safety and Tolerability Study Of Intravenous SBS-1000 in Healthy Adults source ↗

Upcoming milestones

Jan 31, 2027 (ESTIMATED) · 1 · Phase 1 Study of SBS-147 in Healthy Adults · NCT07335913

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Last 2 years.

Jun 16, 2026 Government grant — NIH UG3: $3.08M (annual award, as published), announced Jun 16, 2026. Agency: NIH/NIDA. Source: government award database. source ↗
Jul 29, 2025 Government grant — NIH UG3: $3.98M (annual award, as published), announced Jul 29, 2025. Agency: NIH/NIDA. Source: government award database. source ↗
Jun 26, 2025 Government grant — NIH UG3: $3.14M (annual award, as published), announced Jun 26, 2025. Agency: NIH/NIDA. Source: government award database. source ↗
Nov 14, 2024 Government grant: $19.5M (total, as published), announced Nov 14, 2024. Source: company release on GlobeNewswire. source ↗

Clinical trials (lead sponsor) 2

Record	Title	Phase	Status	Start	Primary completion
NCT07335913	Phase 1 Study of SBS-147 in Healthy Adults	1	Recruiting	Jan 8, 2026	Jan 31, 2027 (estimated)
NCT05721287	A Phase 1, Randomized, Placebo-Controlled Safety and Tolerability Study Of Intravenous SBS-1000 in Healthy Adults	1	Completed	Jan 30, 2023	Aug 15, 2023 (actual)

NIH awards 7

Annual award amounts. Total $24.9M.

Sep 20, 2024 NIH award 1UG3DA059278-01A1 FY2024: $3,957,359 awarded for that fiscal year; activity UG3 (OTHER_NIH); PI REICH, JEFFREY; recipient as written: SPARIAN BIOSCIENCES, INC., NEW YORK CITY, NY. Development of SBS-226, a source ↗
Jul 11, 2024 NIH award 5UG3DA058553-02 FY2024: $4,017,447 awarded for that fiscal year; activity UG3 (OTHER_NIH); PI REICH, JEFFREY; recipient as written: SPARIAN BIOSCIENCES, INC., NEW YORK CITY, NY. Development of sigma recepto source ↗
Aug 2, 2023 NIH award 1UG3DA058553-01 FY2023: $2,886,286 awarded for that fiscal year; activity UG3 (OTHER_NIH); PI REICH, JEFFREY; recipient as written: SPARIAN BIOSCIENCES, INC., NEW YORK CITY, NY. Development of sigma recepto source ↗
Jul 26, 2023 NIH award 5UH3DA048379-05 FY2023: $4,506,061 awarded for that fiscal year; activity UH3 (OTHER_NIH); PI REICH, JEFFREY; recipient as written: SPARIAN BIOSCIENCES, INC., NEW YORK CITY, NY. Arylepoxamides: A new class source ↗
Aug 25, 2022 NIH award 5UH3DA048379-04 FY2022: $4,628,029 awarded for that fiscal year; activity UH3 (OTHER_NIH); PI REICH, JEFFREY; recipient as written: SPARIAN BIOSCIENCES, INC., NEW YORK CITY, NY. Arylepoxamides: A new class source ↗
Sep 20, 2021 NIH award 4UH3DA048379-03 FY2021: $4,595,217 awarded for that fiscal year; activity UH3 (OTHER_NIH); PI REICH, JEFFREY; recipient as written: SPARIAN BIOSCIENCES, INC., NEW YORK CITY, NY. Arylepoxamides: A new class source ↗
Jul 19, 2021 NIH award 1R44DA053846-01 FY2021: $319,223 awarded for that fiscal year; activity R44 (SBIR); PI REICH, JEFFREY; recipient as written: SPARIAN BIOSCIENCES, INC., NEW YORK CITY, NY. Development of CP-analogs as novel source ↗